CClinicalTrials.gg
CompletedNCT04131426Updated Aug 15, 2023

Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia

A Phase 1 interventional study of Remune and EXCAP©® in Cachexia; Cancer, Weight Loss and Lung Cancer, sponsored by University of Rochester. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by University of Rochester · Phase 1, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 8 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this research study is to determine if the use of a nutritional supplement and exercise improve or worsen cachexia.

Read the detailed description

In this study the investigator would like to better understand how cachexia may improve or worsen, and how exercise and nutritional supplements may impact this process. The investigator would like to see whether a nutritional supplement (Remune) with or without a walking and progressive resistance exercise program (EXCAP©®, Exercise for Cancer Patients) can improve symptoms in patients with lung or gastrointestinal cancers with weight loss and cachexia. The investigator would also like to find out if this nutritional supplement and exercise intervention improves physical performance, day-to-day function, quality of life, and how the supplement and/or exercise may affect different markers in the blood over time.

02

Conditions studied

  • Cachexia; Cancer
  • Weight Loss
  • Lung Cancer
  • Gastrointestinal Cancer

Keywords

  • Cachexia; Cancer
  • Weight Loss
  • Exercise
  • Nutritional Supplement
  • Lung Cancer
  • Gastrointestinal Cancer
03

In context

Gastrointestinal Neoplasms

779 studies on the registry are indexed under Gastrointestinal Neoplasms; 231 are open to participants now.

This study's enrollment of 25 is below the median of 60 across 569 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

University of Rochester is the lead sponsor of 715 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Be over the age of 18 years and have a primary diagnosis of colorectal, esophageal, gastric, pancreatic, biliary tract cancer (includes cholangiocarcinoma, gallbladder cancer, and ampullary cancer), or Non-small cell lung cancer (NSCLC) with plans to initiate systemic chemotherapy, targeted therapy or immunotherapy within the next 4 weeks after enrollment.
  • Have been diagnosed as having an unresectable cancer with no plans for surgical intervention during the active study period (12 weeks).
  • Have an ECOG performance score of 0 or 1.
  • Have a life expectancy of >3 months as determined by their primary oncologist.
  • Have experienced at least 2% weight loss of the patient's reported previous body weight over the 6 months prior to enrollment.
  • Have permission from primary oncologist to engage in low to moderate intensity exercise regimen.
  • Be able to read English (since the assessment materials are in printed format).
  • Be able to give written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Have any of the following limitations: unable to perform low-to-moderate intensity exercise regimen.
  • Have had major surgery (excluding diagnostic procedures like laparoscopy, EGD/EUS, esophageal stent placement) in the past 4 weeks.
  • Be experiencing dysphagia that requires enteral or parenteral feeding for nutrition.
  • Be enrolled on hospice at time of consent.
  • Be engaged in an active exercise routine by being identified as in the Active or Maintenance Stage of exercise behavior as assessed by the 1-item Exercise Stages of Change Short Form (67).
  • Use of nutritional supplements containing EPA/DHA within 2 weeks prior to screening
  • Current Use of Vitamin D supplementation or St. John's wort that can influence efficacy and safety parameters. Chronic treatment (>12 weeks prior to screening) with multivitamin tablets is allowed (vitamin tablets must not contain more vitamin D than 150% of the recommended dietary allowance [RDA]).
  • Known hypersensitivity or allergy to any of the study products. Specifically, patients allergic to milk, fish or shellfish will be excluded.
  • Have AST/ALT >3x upper limit of normal (ULN) or >5xULN in those with liver metastases, Serum creatinine >2x ULN, Absolute Neutrophil Count \<1,500/uL, Hemoglobin \<9, Platelet count \<75,000/uL at the time of baseline blood draw or any other Blood chemistry or hematology lab abnormalities that would exclude them from being able to receive standard chemotherapy or interventional clinical trial.
  • Have uncontrolled Diabetes Mellitus as determined by primary oncologist or PI.
05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Remune dosed twice daily

    A nutritional supplement taken twice per day each day and standard care for your cancer as prescribed by your oncologist

    Drug: Remune

  • Experimental
    Remune dosed twice daily and daily exercise with EXCAP

    A nutritional supplement taken twice by day each day and a home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist

    Drug: Remune · Other: EXCAP©®

  • No intervention
    Usual Care

    Usual standard care as prescribed by your oncologist

Interventions

  • DrugRemune

    Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD

  • OtherEXCAP©®

    EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises

    Also known as: Exercise for Cancer Patients

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    measured by adverse event severity and quantity

    Time frame: 3 months

  2. Adherance

    Did 70% of subjects in the supplement arm consume 60% of supplement evening. Patients are asked to report the number of cartons of Remune consumed each day and how much they consumed

    Time frame: 3 months

  3. Recruitment and Retention

    Recruitment of 45 patients (15 per arm) and at least 10 evaluable patients in each arm for retention rate of 66%

    Time frame: 3 months

Secondary outcomes

  1. Proportion of subjects that improve physical function- Walking

    6 minute walk test distance; Participants are given a short warm up and cool down walking protocol in the test walking area in the University. During the 6-minute walk, participants will be asked to wear a sensor that will measure movement ability. The sensor is secured by an ergonomic belt around the participant's waist and allows for free body movement and comfort. Participants walk for a total of 6 minutes and cover as much distance as they can during this time. Upon completion of the test, the total distance walked is used to measure physical performance.

    Time frame: 3 months

  2. Proportion of subjects that improve physical function- Power

    Power will be assessed by the Stair Climb Performance Test (SCPT) which is performed by having subjects safely ascend a flight of stairs (approximately 10 stairs total) as quick and as safely as possible with supervision. The subject can use the handrail as a safety precaution if deemed necessary by the patient, physician, coordinator, or exercise physiologist. Power is calculated by force (calculated by body mass and acceleration due to gravity) multiplied by the velocity (distance/time).

    Time frame: 3 months

  3. Proportion of subjects that improve physical function- Muscle Strength

    Muscular strength will be assessed objectively using The Handgrip Dynamometer Test. The Handgrip Dynamometer Test is a grip strength test used to assess the maximal voluntary contraction generated by the arm muscles. The test is administered with the patient standing with the elbow joint angle held constant at 180 degrees and the medial distal humeral epicondyle held 2 inches from the torso. Trials will be performed in an alternating bilateral sequence, for a total of six attempts (three with each arm). The best score of the three hand-grip trials will be used for right and left limbs to calculate static strength.

    Time frame: 3 months

  4. Porportion of subjects with improved cachexia-related symptoms 3 months

    The Functional Assessment of Anoreix/Cachexia Therapy subscale is a 39-item questionnaire that measures general aspects of quality of life as well as specific anorexia/cachexia-related concerns. This will be collected at pre- and post intervention.

    Time frame: 3 months

07

Study locations

1 site
  • University of Rochester
    Rochester, New York 14642, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04131426
Lead sponsor
University of Rochester
Collaborators
Smartfish AS
Responsible party
Richard Dunne (Assistant Professor - Department of Medicine , Hematology/Oncology, University of Rochester) — Principal investigator
First posted
Oct 18, 2019
Start date
Apr 24, 2020
Primary completion
Jan 13, 2021
Completion
Apr 1, 2022
Last update
Aug 15, 2023

Study contacts

Richard Dunne
principal investigator · University of Rochester Wilmot Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion